Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

advanced breast cancer, particularly for patients with HER2-negative breast cancer and triple-negative breast cancer." 

Positive Phase 2 data for NKTR-102 were recently published in Lancet Oncology in November 2013. (1)  Etirinotecan pegol achieved a confirmed objective response rate by RECIST of 29 percent. NKTR-102 demonstrated a high clinical benefit rate (CR+PR+SD greater than six months) of 37 percent (13/35) in the 14-day group and 49 percent (17/35) in the 21-day group. Six patients experienced 100 percent resolution of all target lesions, with two complete RECIST responses and four near-complete responses.
Patients treated exhibited low rates of alopecia, neuropathy and neutropenia, which are significant adverse events associated with existing breast cancer therapies. Side effects were generally manageable; the most common Grade 3 toxicity was diarrhea (17-23%) typically occurring after three months of therapy.

About the BEACON StudyBEACON is a Phase 3, open-label, randomized, multicenter study of NKTR-102 which enrolled 852 women with locally recurrent or metastatic breast cancer, who have previously been treated with ATC. The trial is being conducted at approximately 150 sites worldwide including North America, Western Europe, Russia and the Republic of Korea.  Nearly half of the patients enrolled in BEACON were located in North America.  Patients were randomized on a 1:1 basis to receive 145 mg/m2 of single-agent NKTR-102 once every three weeks or a single agent of physician's choice.  The physician's choice agents include: ixabepilone, vinorelbine, gemcitabine, eribulin, or a taxane.  Randomization was stratified by geographic region, prior use of eribulin and receptor status. 

The primary endpoint of the BEACON study is overall survival; secondary endpoints include progression-free survival, objective tumor response
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Lupin , Strides ... MPP Sub-licensees to Fourteen Companies     ... expansion of its network of generic manufacturers to 14 companies ... antiretrovirals (ARVs). New companies Lupin and Strides Arcolab recently signed ... the MPP licensed from ViiV Healthcare two months after its ...
(Date:7/1/2015)... July 1, 2015  Celsion Corporation (NASDAQ: CLSN ... Michael H. Tardugno , Chairman, President and CEO, ... Healthcare Conference on Wednesday, July 8, 2015, at 4:15 ... Parker Meridien Hotel located at 119 W. 56th Street, ... A copy of the presentation will be available ...
(Date:7/1/2015)... July 1, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... Radie , president and chief executive officer, is ... He will provide an update on Egalet,s marketed ... Nasal Spray, approved product OXAYDO ™ (oxycodone ...
Breaking Medicine Technology:The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
... First Totally Noninvasive Cardiovascular Monitor... -- AMSTERDAM, November 18, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
... 2010 Royal Philips Electronics (NYSE: PHG, AEX: ... of neonatal medical equipment, announced today that they ... a more complete portfolio of perinatal care solutions. ... home monitoring, neonatal incubators and warmers, jaundice management, ...
Cached Medicine Technology:BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 2BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 3BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 4BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 5BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 6BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 7BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States 8Philips and Atom Medical Corporation Announce Strategic Alliance to Provide a Complete Neonatal and Perinatal Offering 2Philips and Atom Medical Corporation Announce Strategic Alliance to Provide a Complete Neonatal and Perinatal Offering 3
(Date:7/1/2015)... ... 01, 2015 , ... Sir Fazle Hasan Abed, BRAC’s founder and chairperson, was ... has been recognised for his outstanding contribution to enhancing the world's production and distribution ... the World Food Prize Foundation, announced this year’s winner at a ceremony at the ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced that they will welcome four new members to their industry leading Scientific ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC Corporation today announced the ... natural blue food coloring. Construction of the plant, which is located on the ... began in May 2014. After commissioning, commercial production is expected to begin in ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will ... of America (HCA), as it further expands its Strategic Alliance Partnership Program for ... this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon ...
(Date:7/1/2015)... ... ... The 28th annual Charity Horse Show hosted by the Mid-South Horse Show ... in Pugh Bourne Park, 343 Oakfield Road. The event will again benefit Youth Town. ... a silent auction and concessions. , Horses and riders from around the country will ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... , Recent CBO analysis understates key factors ... new actuarial analysis by Oliver Wyman, Inc. finds that average ... 54 percent higher than they are today five years after ... Care Act (PPACA), excluding the impact of medical inflation. ...
... ... HPV test, not by Pap test – HiFi DNA Tech sues FDA on December 11 ... ... Gynecologists has confirmed that the invasive cancer workup procedure, also known as colposcopic biopsy, ...
... , MUNICH, Germany, PARSIPPANY, N.J. ... one Enterprise Image Intelligence® company, and Visage Imaging® Inc., ... PME) announced today that they have entered into a ... for the clinical and preclinical imaging domain. , The ...
... , CHAPEL HILL, N.C., Dec. 3 To ... has created a named award for a long-serving employee, ... inaugural Pauline Muhuhu Leadership Award, with a small cash prize, ... week. , With the annual award, IntraHealth seeks to ...
... ... space, announced that international medical quality authority, Dr. David Jaimovich, has joined its Medical ... ... leading global healthcare company specializing in the emerging medical travel space, announced that international ...
... also find that children exposed to smoke are at risk ... Add colorectal cancer to the list of malignancies caused by ... two. , And other studies are providing more bad news ... in the December issue of Epidemiology, Biomarkers & Prevention ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2Health News:Visage Imaging and Definiens Announce Partnership 2Health News:Visage Imaging and Definiens Announce Partnership 3Health News:Inaugural 'Health Worker Leadership Award' Honors Kenyan Midwife, IntraHealth Senior Leader 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4
... complete imaging access, with nearly 100 percent ... imaging C-Arms can pan from head to ... patient. Anesthesiologists will appreciate this table for ... construction, and ease of operation. The key ...
...
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: